Company intelligence / Profile preview
Q BioMed Inc.
- Ownership
- Private
- Development stage
- Commercial
Overview
Q BioMed Inc. operates as a biomedical acceleration and development company focused on licensing and acquiring undervalued biomedical assets. Its lead asset, Uttroside-B for liver cancer, has received FDA Orphan Drug Designation and encouraging preclinical results; the company also markets Strontium Chloride Sr89/Metastron for metastatic bone pain and develops programs in glaucoma and rare pediatric autism. The pipeline spans from preclinical to commercial stages.
- Therapeutic areas
- OphthalmologyOncologyPsychiatry
- Modalities
- Small molecules (e.g., Uttroside-B)Radiopharmaceuticals (e.g., Strontium Chloride Sr-89/Metastron)
- Industry
- Biotech
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Q BioMed Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Q BioMed Inc..